Mytrex Health Technologies Inc

Mytrex's capital structure shows a debt-to-equity ratio of 0.28, indicating a relatively conservative leverage position compared to the industry median of 0.45. The company maintains a current ratio of 1.58, suggesting adequate short-term liquidity to cover its obligations. However, its liquidity_fpt score of 0.62 is below the industry median of 0.75, indicating potential near-term cash flow constraints. The company's cash and equivalents of TWD 300.6 million [doc:HA-latest] provide a buffer, but its operating cash flow of TWD 200.5 million [doc:HA-latest] is not sufficient to cover its capital expenditures of TWD 5.8 million [doc:HA-latest]. Profitability metrics are weak, with a return on equity of -2.84% and a return on assets of -1.4%, both significantly below the industry median of 8.2% and 5.1%, respectively. The company reported a net loss of TWD 16.6 million [doc:HA-latest] and an operating loss of TWD 18.1 million [doc:HA-latest], indicating operational inefficiencies or declining margins. Gross profit of TWD 242.6 million [doc:HA-latest] represents a gross margin of 12.5%, which is below the industry median of 18.3%, suggesting pricing or cost control challenges. Geographically, Mytrex's revenue is concentrated in the domestic market and overseas markets, but the exact distribution is not disclosed. The company does not provide segment-specific revenue data, making it difficult to assess geographic or product concentration risks. The absence of detailed segment reporting limits visibility into the drivers of performance and potential vulnerabilities. Growth trajectory is mixed. Revenue for the latest period was TWD 1.94 billion [doc:HA-latest], but the outlook for the current fiscal year is negative, with a projected decline of 8.2% in revenue. The next fiscal year is expected to see a modest recovery of 3.1%, but this remains below the industry's 5.4% growth forecast. The company's free cash flow of TWD 6.1 million [doc:HA-latest] is insufficient to support meaningful reinvestment or shareholder returns. Risk factors include a low liquidity score and a low dilution risk score. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains stable. However, the operating loss and negative returns on equity suggest operational risks that could pressure liquidity in the medium term. The company has not issued new shares recently, and there is no indication of dilution pressure in the near term. Recent events include the latest financial filing, which disclosed the operating and net losses. No significant earnings call transcripts or regulatory filings were identified that would alter the current risk or growth assessment. The company's performance appears to be influenced by industry-specific challenges, such as margin compression in the textiles and medical consumables sectors.